| Dr Christian James Duplass, DO | |
|
1161 Mcdermott Dr, Suite 101, West Chester, PA 19380-4064 | |
| (610) 701-7011 | |
| (610) 429-5199 |
| Full Name | Dr Christian James Duplass |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 25 Years |
| Location | 1161 Mcdermott Dr, West Chester, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275582025 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | OS-010686-L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Penn Medicine Home Health | Bala cynwyd, PA | Home health agency |
| Paoli Hospital | Paoli, PA | Hospital |
| Main Line Hospital Lankenau | Wynnewood, PA | Hospital |
| Chester County Hospital | West chester, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Main Line Healthcare | 1951215201 | 894 |
News Archive
After 7 days of recovery from a 10-day period of deficient sleep, participants in a small study had recovered their pre-sleep deprivation reaction speed, but had not fully recovered on any other measures of function.
This Wednesday the Food and Drug Administration (FDA) released guidelines regarding agency approval for certain types of new products to be obtained by tobacco-product makers. FDA announced that products such as cigarettes, roll-your-own tobacco and smokeless products that were introduced or changed after Feb. 15, 2007 must be reviewed by the agency to show that they are "substantially equivalent" to products commercially available on Feb. 15, 2007.
Investigators at the Cedars-Sinai Regenerative Medicine Institute have identified new molecular abnormalities in the diabetic cornea that could contribute to eye problems in affected patients.
Investigators at Children's Hospital Los Angeles have determined that in children receiving gadolinium as a contrast agent to enhance MRI examinations, signal changes attributed solely to deposition of this material in the brain are not dependent on the amount of gadolinium administered but rather these changes are seen in association with other factors such as the presence of brain tumors and treatment using brain irradiation. Results of the study were just published in the journal, Radiology.
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
› Verified 5 days ago
| Entity Name | Main Line Healthcare |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922077643 PECOS PAC ID: 1951215201 Enrollment ID: O20040308000373 |
News Archive
After 7 days of recovery from a 10-day period of deficient sleep, participants in a small study had recovered their pre-sleep deprivation reaction speed, but had not fully recovered on any other measures of function.
This Wednesday the Food and Drug Administration (FDA) released guidelines regarding agency approval for certain types of new products to be obtained by tobacco-product makers. FDA announced that products such as cigarettes, roll-your-own tobacco and smokeless products that were introduced or changed after Feb. 15, 2007 must be reviewed by the agency to show that they are "substantially equivalent" to products commercially available on Feb. 15, 2007.
Investigators at the Cedars-Sinai Regenerative Medicine Institute have identified new molecular abnormalities in the diabetic cornea that could contribute to eye problems in affected patients.
Investigators at Children's Hospital Los Angeles have determined that in children receiving gadolinium as a contrast agent to enhance MRI examinations, signal changes attributed solely to deposition of this material in the brain are not dependent on the amount of gadolinium administered but rather these changes are seen in association with other factors such as the presence of brain tumors and treatment using brain irradiation. Results of the study were just published in the journal, Radiology.
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christian James Duplass, DO 1161 Mcdermott Dr, Suite 101, West Chester, PA 19380-4064 Ph: (610) 701-7011 | Dr Christian James Duplass, DO 1161 Mcdermott Dr, Suite 101, West Chester, PA 19380-4064 Ph: (610) 701-7011 |
News Archive
After 7 days of recovery from a 10-day period of deficient sleep, participants in a small study had recovered their pre-sleep deprivation reaction speed, but had not fully recovered on any other measures of function.
This Wednesday the Food and Drug Administration (FDA) released guidelines regarding agency approval for certain types of new products to be obtained by tobacco-product makers. FDA announced that products such as cigarettes, roll-your-own tobacco and smokeless products that were introduced or changed after Feb. 15, 2007 must be reviewed by the agency to show that they are "substantially equivalent" to products commercially available on Feb. 15, 2007.
Investigators at the Cedars-Sinai Regenerative Medicine Institute have identified new molecular abnormalities in the diabetic cornea that could contribute to eye problems in affected patients.
Investigators at Children's Hospital Los Angeles have determined that in children receiving gadolinium as a contrast agent to enhance MRI examinations, signal changes attributed solely to deposition of this material in the brain are not dependent on the amount of gadolinium administered but rather these changes are seen in association with other factors such as the presence of brain tumors and treatment using brain irradiation. Results of the study were just published in the journal, Radiology.
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
› Verified 5 days ago
Dr. Paul Debacco, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1161 Mcdermott Dr., Suite 101, West Chester, PA 19380 Phone: 610-701-7011 Fax: 610-429-5199 | |
Miss Sara Elizabeth Sterling, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 701 E Marshall St, West Chester, PA 19380 Phone: 610-431-5000 Fax: 610-431-5025 | |
Levelle Drose-bigatel, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1601 Mcdaniel Dr, Suite 50, West Chester, PA 19380 Phone: 484-905-8000 Fax: 484-905-8005 | |
Dr. George Nicholas Spyropoulos, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1646 W Chester Pike, Suite 12, West Chester, PA 19382 Phone: 610-738-9002 Fax: 610-738-9101 | |
Dr. Louis H Hirshberg, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1114 Lincoln Dr, West Chester, PA 19380 Phone: 610-608-4051 | |
Mary Brigandi, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 701 E Marshall St, West Chester, PA 19380 Phone: 610-431-5000 Fax: 610-738-2356 | |
Boyd C. Myers, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1240 Wrights Lane, West Chester, PA 19380 Phone: 610-431-1210 Fax: 610-594-2625 |